by Richard Daverman, PhD
October 11, 2013 -- Sihuan Pharma reported that the CFDA has approved its application to begin clinical trials of pirotinib, a Category 1.1 innovative drug that was developed by the company’s own R&D operation. Although Sihuan is known for its cardio-cerebral vascular products, it also produces treatments for cancer. Pirotinib is the first cancer drug that Sihuan discovered and developed itself. More details....
Stock Symbol: (HK: 0460)
Help employers find you! Check out all the jobs and post your resume.
